Mechanism of action<unk>  blocks IL-2 receptors containing the alpha subunit (CD25), which include the high-affinity receptors. Medium-affinity receptors, on the other hand, consist of two beta subunits (CD122) and are not affected by<unk> . While the exact mechanism is unknown, the net effect is a reduction of T-cell responses and expansion of CD56bright natural killer cells. Pharmacokinetics After subcutaneous injection of a single dose,<unk>  has a bioavailability of about 90% and reaches highest blood plasma levels after 5 to 7 days. Given every four weeks, steady state concentrations are found after the fourth dose. It is expected that<unk> , like other antibodies, is degraded by proteases to peptides and finally amino acids, and that it does not interact with cytochrome P450 liver enzymes. The biological half-life is 21 days. Patients who developed antibodies against<unk>  eliminated it 19% faster.
Daclizumab
Tocilizumab
Brolucizumab
Satralizumab
Ravulizumab
Reslizumab
Natalizumab
Benralizumab